Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Conferences
Guide to authors
Online submissionOnline submission
Permissions
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
naturereprints
About this site
For librarians
 
NPG Resources
Bioentrepreneur
Nature Reviews Drug Discovery
Nature
Nature Medicine
Nature Genetics
Nature Reviews Genetics
Nature Methods
Nature Chemical Biology
news@nature.com
Clinical Pharmacology & Therapeutics
Nature Conferences
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Biotechnology  20, 1246 - 1250 (2002)
Published online: 11 November 2002; | doi:10.1038/nbt757

Growth factor engineering by degenerate homoduplex gene family recombination

Wayne M. Coco1, 2, Lance P. Encell1, 2, William E. Levinson1, Michael J. Crist1, 3, A. Katrina Loomis1, 2, Laura L. Licato1, 4, Joseph J. Arensdorf1, 5, Nicole Sica1, 2, Philip T. Pienkos1, 6 & Daniel J. Monticello1, 7

1  Enchira Biotechnology Corporation, 4200 Research Forest Drive, The Woodlands, TX 77381.

2  Current address: Tanox, Inc., Houston, TX 77025.

3  Current address: Lexicon Genetics, Inc., The Woodlands, TX 77381.

4  Current address: Isolagen, Inc., Houston, TX 77042.

5  Current address: Baker Petrolite, Sugar Land, TX 77478.

6  Current address: Fermentation Developments, The Woodlands, TX 77381.

7  Current address: Molecular Logix Inc., 4200 Research Forest Drive, The Woodlands, TX 77381.

Correspondence should be addressed to Wayne M. Coco wcoco@tanox.com
There is great interest in engineering human growth factors as potential therapeutic agonists and antagonists. We approached this goal with a synthetic DNA recombination method. We aligned a pool of "top-strand" oligonucleotides incorporating polymorphisms from mammalian genes encoding epidermal growth factor (EGF) using multiple polymorphic "scaffold" oligonucleotides. Top strands were then linked by gap filling and ligation. This approach avoided heteroduplex annealing in the linkage of highly degenerate oligonucleotides and thus achieved completely random recombination. Cloned genes from a human−mouse chimeric library captured every possible permutation of the parental polymorphisms, creating an apparently complete recombined gene-family library, which has not been previously described. This library yielded a chimeric protein whose agonist activity was enhanced 123-fold. A second library from five mammalian EGF homologs possessed the highest reported recombination density (1 crossover per 12.4 bp). The five-homolog library yielded the strongest-binding hEGF variant yet reported. In addition, it contained strongly binding EGF variants with antagonist properties. Our less biased approach to DNA shuffling should be useful for the engineering of a wide variety of proteins.

 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

Open Innovation Challenges

naturejobs

Competing financial interests
Figures & Tables
Export citation
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Biotechnology
ISSN: 1087-0156
EISSN: 1546-1696
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | Conferences | For authors | Online submission | Permissions | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | naturereprints | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2002 Nature Publishing Group | Privacy policy